Dr. Cosgrove on Retreatment With PARP Inhibitors in Ovarian Cancer
Casey M. Cosgrove, MD, gynecologic oncologist, The Ohio State University Comprehensive Cancer Center–James, and assistant professor, Department of Gynecologic Oncology, The Ohio State University College of Medicine, discusses retreatment with PARP inhibitors in recurrent ovarian cancer.
Casey M. Cosgrove, MD, gynecologic oncologist, The Ohio State University Comprehensive Cancer Center—James, and assistant professor, Department of Gynecologic Oncology, The Ohio State University College of Medicine, discusses retreatment with PARP inhibitors in recurrent ovarian cancer.
A data gap exists when it comes to treating patients who have already received a PARP inhibitor, says Cosgrove. With the SOLO-1 data, and now the PRIMA data, more patients are going to receive PARP inhibitors up front as part of their maintenance treatment after primary therapy, he adds. However, there are no robust data to suggest that retreatment with a different PARP inhibitor would be effective.
The question of retreatment is being evaluated in the phase IIIb OReO trial (NCT03106987). In this trial, patients who receive chemotherapy followed by maintenance PARP inhibition and recur will receive platinum-based chemotherapy and be randomized to either olaparib (Lynparza) or placebo. The study will shed light on whether using a PARP inhibitor after another PARP inhibitor is a viable strategy, concludes Cosgrove.
